ICH Q3C Solvent Risk Review for API Manufacturing Procurement

Buying a solvent for active pharmaceutical ingredient manufacture is not simply a question of assay, price and delivery date. The material can be a reaction medium, extraction aid, crystallisation solvent, wash or process carrier; its role, removal route and potential carryover determine what evidence a buyer needs. An ICH Q3C solvent risk review helps procurement ask the right questions without turning a purchase order or a supplier statement into a regulatory conclusion.

ICH Q3C addresses residual organic volatile chemicals used or produced in manufacture of drug substances, excipients or drug products. It recommends avoiding Class 1 solvents where possible, limiting Class 2 solvents, and using less toxic Class 3 solvents where practical. The current ICH Q3C(R9) text is available through the European Medicines Agency. The guideline is a patient-safety framework; it does not certify a supplier, approve a process or set a universal incoming-solvent specification. The product-specific decision remains with the manufacturer and its quality system.

Start with the process role, not the solvent label

For API manufacturing solvent procurement, record the exact material identity, grade, supplier, manufacturing site, intended process step, maximum planned charge, recovery or recycle route, downstream removal steps and the product or intermediate involved. A name such as “ethanol,” “acetonitrile” or “process solvent” is not enough: record the controlled specification, CAS identifier where appropriate, relevant impurity profile, water limit, packaging and product-code revision. If the solvent is recovered, blended or transferred before use, include those operations in the map.

Then ask what could reasonably remain in the drug substance or be carried into later steps. Q3C explains that testing is needed for solvents used or produced in manufacture or purification when those processes are known to result in their presence. That does not mean every incoming drum should be tested for every listed solvent. It means the process owner should identify the solvents that matter to the route and establish a justified control strategy. Procurement should capture that decision rather than infer it from a generic “pharma grade” label.

Connect the request to the product portfolio and retain the agreed evidence with controlled documentation. This keeps commercial specifications, quality agreements and analytical expectations together while allowing the manufacturer to protect confidential synthesis details.

Use the ICH classes as a risk prompt

Class 1, Class 2 and Class 3 describe different residual-solvent risk categories in Q3C; they are not purchasing tiers. A solvent’s class does not by itself answer whether it is suitable for a particular reaction, whether a process can remove it, or whether its impurity profile is acceptable. The buyer should therefore avoid asking a supplier to declare broad “Q3C compliance” without defining the material, use and evidence scope.

For each candidate, ask the technical owner to state: is the solvent intentionally used, generated, recovered or potentially introduced through another material; what is the anticipated residual-solvent control approach; what analytical method and reporting capability support that approach; and what process changes would require reassessment? When a Class 1 solvent is proposed, escalate early. When a Class 2 solvent is used, do not substitute its permitted daily exposure or concentration table for a process-specific assessment. When a Class 3 solvent is selected, continue to assess process, quality and patient-impact questions relevant to the product.

The guideline also says “likely to be present” relates to solvents used in the final manufacturing step and to earlier solvents not consistently removed by a validated process. That is a useful procurement question: request a process-owner statement on whether removal is controlled, rather than treating a historical supplier CoA as proof of downstream performance.

Specify evidence that can be released and reviewed

A practical residual solvent supplier qualification package begins with a current specification and CoA format, including methods, units, typical versus release limits, lot identity and the authorised release source. Add SDS revision, manufacturing-site identity, packaging configuration, transport conditions where relevant, traceability route, stability or retest information where supplied, and contact points for quality notifications. Agree how a buyer may request lot-specific documents and how corrections are issued.

Evidence has limits. A CoA reports the tested attributes of a lot according to its stated method; it does not prove residual levels in a customer’s API. A supplier certificate does not establish that a process removal step is validated. Conversely, a supplier cannot always disclose every upstream raw-material detail. Use a controlled confidentiality route for information genuinely needed for technical review, and record what was reviewed, its version and the conclusion. The testing support route can help align test-method discussions to the actual qualification plan.

Build an incoming control plan that matches risk

Set incoming checks based on the material and intended application. Identity confirmation, appearance, water, assay, non-volatile residue, selected organic impurities or elemental limits may be relevant depending on the solvent and process; the appropriate attributes and acceptance criteria are site-specific. Define sampling, sample retention, release status, deviation handling and disposition before the first production delivery. If testing is outsourced, make sure the report can be matched to the lot and method version.

Trend representative lots rather than relying only on one approval sample. Compare supplier release data with incoming results, complaints, process observations and any relevant residual-solvent results downstream. A shift within the supplier’s specification can still warrant review if it affects a qualified process window. The goal is not to promise a performance number; it is to make a change visible before it becomes an unexplained production variable.

Put changes through the same gate as new material

Define notification triggers in the quality agreement: manufacturing site, route, raw-material source where contractually relevant, purification, specification, test method, reporting limit, packaging, closure, product code, SDS, storage condition, batch numbering or legal manufacturer. Review each notification against the approved use. A new pack, a different water limit or a revised impurity method may have different consequences for a drying-sensitive or trace-analysis process.

Assign roles clearly. Procurement owns the commercial request and approved-source status; quality owns document control and supplier qualification; analytical and process teams own technical suitability; regulatory personnel determine submission or market implications; manufacturing releases use only after the required review. Link released lots to batch traceability so a later investigation can recover the applicable material and document revisions.

API solvent purchasing checklist

• Identify the exact solvent, grade, site, lot route, pack and intended API process step.
• Map possible residual presence and the downstream removal strategy with the process owner.
• Use ICH Q3C classes to prompt review, not as a blanket suitability claim.
• Obtain controlled specifications, CoA format, methods, traceability and notification contacts.
• Set risk-based incoming controls and retain samples and records as appropriate.
• Trend representative production lots against the qualified process window.
• Review site, method, specification, package and route changes before use.
• Escalate unresolved patient-safety or regulatory questions to qualified specialists.

A disciplined GMP solvent purchasing checklist makes the evidence path clear from supplier selection to batch use. For a defined solvent, pack and process requirement, review quality support, supply planning and request an API-solvent review.